Photo of Jaymin M Patel,  MD

Jaymin M Patel, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2100
Fax: (617) 975-5665


jpatel1@bidmc.harvard.edu

Jaymin M Patel, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Clinical Instructor, Medicine, Harvard Medical School
  • Medical Oncologist, Breast Oncology Program, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Patel is interested in translational research to improve diagnostics and therapeutics for breast cancer patients. Overall academic interests include nanoparticle technology, genomic instability, tumor targeting and personalized medicine. As with prior projects, he will strive to facilitate a bi-directional transfer of hypothesis-generating ideas between breast cancer clinic and scientific leaders across the DF/HCC program. He currently serves as an investigator on a number of breast cancer-specific clinical trials. In addition, is working with Dr. Senthil Muthuswamy’s lab to establish a pipeline for organoid development for the purpose of personalized therapeutic screening and interrogation of resistance mechanisms. Also, plans to collaborate with Dr. Gerburg Wulf’s lab to perform pre-clinical testing on a novel cell-penetrating antibody that targets DNA-repair deficient cells.

Publications

Powered by Harvard Catalyst
  • Chen Z, Patel JM, Noble PW, Garcia C, Hong Z, Hansen JE, Zhou J. A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors. 2016; 7:59965-59975. PubMed
  • Patel JM, Knopf J, Reiner E, Bossuyt V, Epstein L, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Platt J, Shi W, Gershkovich P, Hatzis C, Pusztai L. Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. 2016; 7:22064-76. PubMed
  • Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC. Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica 2013; 98:789-92. PubMed